stantial support derives from evidence of severe clinical effects caused by arsenic contamination of milk powder used for preparation of milk substitute for infants. The reports on this tragedy appeared in Japanese language journals and have only been recently reviewed in English. 8 Records show that the prepared milk contained arsenic concentrations of 2 mg/L or more. Clinical poisoning occurred after total doses of approximately 60 mg within approximately 1 month. Limited follow-up of the children exposed to contaminated milk powder revealed neurologic diseases, neurobehavioral dysfunction, and decreased cognitive skills. 8 Judging from the Japanese study, some neurotoxicity would likely be present among the Bengali children at the time of examination, at least among those with the highest exposure levels, Furthermore, if the evidence on lead and methylmercury is of any guidance in regard to arsenic neurotoxicity, subclinical effects might occur even at exposure levels that are 1/100 of the doses that cause clinical poisoning. Accordingly, developmental arsenic exposure within the ranges studied by von Ehrenstein et al could be associated with adverse neurobehavioral effects, although not detected in this study. Given the current information on arsenic neurotoxicity, the absence of significant associations in the Bengali study should therefore not be taken as evidence of safety of these arsenic exposure levels.
The issue of developmental neurotoxicity has been ignored in previous risk assessments of environmental arsenic exposure. Thus, cancer risk has been the basis for current exposure limits, 9, 10 whereas developmental neurotoxicity has not been considered at all. It would seem unwise to overlook arsenic as a likely developmental neurotoxicant. This issue should be an important priority in environmental epidemiology research.
